Spike S1 (B.1.617 Variant) (SARS-CoV-2) : ACE2 TR-FRET Assay Kit

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection.The SARS-CoV-2 variant B.1.617 was originally discovered in India. This variant was the precursor to the B.1.617.1 (Kappa) and the B.1.617.2 (Delta) variants. It contains mutations L452R, E484Q, D614G and P681R.

Catalog #NameAmountStorage100705ACE2, His-Tag, Eu-labeled*2 x 2 µg-80°C101123Spike S1* (B.1.617 Variant), Avi-His-tag, Biotin Labeled (16-685) (SARS-CoV-2) 2 x 25 µg-80°CDye-labeled acceptor3 x 10 µl-20°C799533x ACE2-Spike TR-FRET Buffer4 ml-20°C79969384-well white microplate1Room Temp*The initial concentration of both ACE2 and Spike S1 is lot-specific and will be indicated on the tube containing the protein.

Troubleshooting GuideVisitbpsbioscience.com/assay-kits-faqfor detailed troubleshooting instructions. For all further questions, please email[email protected]